explore -WSS

explore

author：explore 2025-09-30 18:17:05 - browse：297

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

knowledge

WSS

Dementia risk linked to living in disadvantaged areas: Study

Organ aging and disease risk measured by new blood test

Mystery swirls around US soldier who entered North Korea days ago, officials say

How to pay for weight loss drugs and save Medicare

UnitedHealth’s Optum accused of antitrust violations in California

How to pay for weight loss drugs and save Medicare

focus

explore

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

What to do when lifesaving products contribute to climate change

Continuity nursing helped my family in our darkest PICU moments

Mayo Clinic plans $5B tech

Wildfire smoke exposes gaps in outdoor worker protections

As biotech industry slumps, bioscience job market is upside down

Novavax promises a turnaround & Lilly roils the obesity market

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

New air purifier tech could be key to improving indoor air quality

Will the market for weight loss drugs really reach $100 billion?

hotspot

What to do when lifesaving products contribute to climate change

'CMA Fest' 2023: How to watch, who is performing and more

Cigna, Humana reportedly in talks to merge

Pediatric cancer treatments threatened by a new FDA policy

When a patient nears the end, a feared therapy can comfort

Fetal surgery at risk from Dobbs and new abortion restrictions

Wikipedia

knowledge

focus

focus